Skip to main content
Erschienen in: European Archives of Oto-Rhino-Laryngology 1/2018

25.10.2017 | Rhinology

Assessment of the effectiveness of cyclosporine nasal spray in an animal model of allergic rhinitis

verfasst von: Erol Senturk, Yavuz Selim Yildirim, Remzi Dogan, Orhan Ozturan, Eray Metin Guler, Mehmet Serif Aydin, Abdurrahim Kocyigit, Mukaddes Esrefoglu, Ilker Kocak

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study is to show if cyclosporine has an antiallergic role in a rat model of ovalbumin-induced allergic rhinitis. The 54 rats were divided into six equal groups. The first group was a negative control group without induced allergic rhinitis; the second group a positive control with induced allergic rhinitis not receiving treatment. The remaining four groups, after induction of allergic rhinitis, received intranasal cyclosporine treatment in doses of 0.05, 0.1, or 0.2% or nasal steroid treatment. In the biochemical examination, on the surface of the tissue tumor necrosis factor (TNF) interferon (IFN), interleukin (IL)-5, IL-13, as well as IL-2, IL-4, IL-17A, and IgE were studied. Histologically, ciliary loss, increase of goblet cells, vascular congestion, and the degree of eosinophil infiltration were rated. In all treatment groups, on average, a significant reduction in all histological and biochemical values was found compared to the positive control group. Comparing each of the three cyclosporine-using groups with the group of nasal corticosteroid did not show any significant difference in the average scores. Cyclosporine nasal drops are effective to be used in an animal model of experimental allergic rhinitis without systemic effects.
Literatur
1.
Zurück zum Zitat Matsuda S, Koyasu S (2000) Mechanisms of action of cyclosporine. Immunopharmacology 47:119–125CrossRefPubMed Matsuda S, Koyasu S (2000) Mechanisms of action of cyclosporine. Immunopharmacology 47:119–125CrossRefPubMed
4.
Zurück zum Zitat Shimizu T, Hirano H, Majima Y, Sakakura Y (2000) A mechanism of antigen-induced mucus production in nasal epithelium of sensitized rats. A comparison with lipopolysaccharide-induced mucus production. Am J Respir Crit Care Med 161:1648–1654. doi:10.1164/ajrccm.161.5.9908101 CrossRefPubMed Shimizu T, Hirano H, Majima Y, Sakakura Y (2000) A mechanism of antigen-induced mucus production in nasal epithelium of sensitized rats. A comparison with lipopolysaccharide-induced mucus production. Am J Respir Crit Care Med 161:1648–1654. doi:10.​1164/​ajrccm.​161.​5.​9908101 CrossRefPubMed
6.
Zurück zum Zitat Zeiger R, Schatz M (2000) Effect of allergist intervention on patient-centered and societal outcomes: allergists as leaders, innovators, and educators. J Allergy Clin Immunol 106(6):995–1018CrossRefPubMed Zeiger R, Schatz M (2000) Effect of allergist intervention on patient-centered and societal outcomes: allergists as leaders, innovators, and educators. J Allergy Clin Immunol 106(6):995–1018CrossRefPubMed
7.
Zurück zum Zitat Nagai H, Teramachi H, Tuchiya T (2006) Recent advances in the development of anti-allergic drugs. Allergol Int 55(1):35–42CrossRefPubMed Nagai H, Teramachi H, Tuchiya T (2006) Recent advances in the development of anti-allergic drugs. Allergol Int 55(1):35–42CrossRefPubMed
9.
Zurück zum Zitat Shimizu S, Hattori R, Majima Y, Shimizu T (2009) Th2 cytokine inhibitor suplatast tosilate inhibits antigen-induced mucus hypersecretion in the nasal epithelium of sensitized rats. Ann Otol Rhinol Laryngol 118:67–72CrossRefPubMed Shimizu S, Hattori R, Majima Y, Shimizu T (2009) Th2 cytokine inhibitor suplatast tosilate inhibits antigen-induced mucus hypersecretion in the nasal epithelium of sensitized rats. Ann Otol Rhinol Laryngol 118:67–72CrossRefPubMed
10.
Zurück zum Zitat Sperr WR, Agis H, Semper H et al (1997) Inhibition of allergen-induced histamine release from human basophils by cyclosporine A and FK-506. Int Arch Allergy Immunol 114:68–73CrossRefPubMed Sperr WR, Agis H, Semper H et al (1997) Inhibition of allergen-induced histamine release from human basophils by cyclosporine A and FK-506. Int Arch Allergy Immunol 114:68–73CrossRefPubMed
11.
Zurück zum Zitat Narita SI, Asakura K, Shiraski H et al (1998) Effects of cyclosporin A and glucocorticosteroids on antigen-induced hypersensitivity to histamine in a guinea pig model of allergic rhinitis. Inflamm Res 47:62–66CrossRefPubMed Narita SI, Asakura K, Shiraski H et al (1998) Effects of cyclosporin A and glucocorticosteroids on antigen-induced hypersensitivity to histamine in a guinea pig model of allergic rhinitis. Inflamm Res 47:62–66CrossRefPubMed
12.
Zurück zum Zitat Agathos S, Marshall J, Moraiti C (1986) Physiological and genetic factors for process development of cyclosporine fermentations. J Ind Microbiol 1:39. doi:10.1007/BF01569415 CrossRef Agathos S, Marshall J, Moraiti C (1986) Physiological and genetic factors for process development of cyclosporine fermentations. J Ind Microbiol 1:39. doi:10.​1007/​BF01569415 CrossRef
17.
Zurück zum Zitat Alexander AG, Barnes NC, Kay AB (1992) Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 339:324–328CrossRefPubMed Alexander AG, Barnes NC, Kay AB (1992) Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 339:324–328CrossRefPubMed
19.
Zurück zum Zitat Loria MP, Dambra PP, D’Oronzio L et al (2001) Cyclosporin A in patients affected by chronic idiopathic urticaria: a therapeutic alternative. Immunopharmacol Immunotoxicol 23:205–213. doi:10.1081/IPH-100103860 CrossRefPubMed Loria MP, Dambra PP, D’Oronzio L et al (2001) Cyclosporin A in patients affected by chronic idiopathic urticaria: a therapeutic alternative. Immunopharmacol Immunotoxicol 23:205–213. doi:10.​1081/​IPH-100103860 CrossRefPubMed
20.
Zurück zum Zitat Stevenson D, Tauber J, Reis BL (2000) Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 107:967–974CrossRefPubMed Stevenson D, Tauber J, Reis BL (2000) Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 107:967–974CrossRefPubMed
21.
Zurück zum Zitat Bentley AM, Jacobson MR, Cumberworth V et al (1992) Immunohistology of the nasal mucosa in seasonal allergic rhinitis: increases in activated eosinophils and epithelial mast cells. J Allergy Clin Immunol 89:877–883CrossRefPubMed Bentley AM, Jacobson MR, Cumberworth V et al (1992) Immunohistology of the nasal mucosa in seasonal allergic rhinitis: increases in activated eosinophils and epithelial mast cells. J Allergy Clin Immunol 89:877–883CrossRefPubMed
23.
Zurück zum Zitat Shirakawa T, Enomoto T, Shimazu S, Hopkin JM (1997) The inverse association between tuberculin responses and atopic disorder. Science 275:77–79CrossRefPubMed Shirakawa T, Enomoto T, Shimazu S, Hopkin JM (1997) The inverse association between tuberculin responses and atopic disorder. Science 275:77–79CrossRefPubMed
25.
Zurück zum Zitat Chen ST, Sun HL, Lu KH et al (2006) Correlation of immunoglobulin E, eosinophil cationic protein, and eosinophil count with the severity of childhood perennial allergic rhinitis. J Microbiol Immunol Infect 39:212–218PubMed Chen ST, Sun HL, Lu KH et al (2006) Correlation of immunoglobulin E, eosinophil cationic protein, and eosinophil count with the severity of childhood perennial allergic rhinitis. J Microbiol Immunol Infect 39:212–218PubMed
26.
Zurück zum Zitat Winther L, Moseholm L, Reimert CM et al (1999) Basophil histamine release, IgE, eosinophil counts, ECP, and EPX are related to the severity of symptoms in seasonal allergic rhinitis. Allergy 54:436–445CrossRefPubMed Winther L, Moseholm L, Reimert CM et al (1999) Basophil histamine release, IgE, eosinophil counts, ECP, and EPX are related to the severity of symptoms in seasonal allergic rhinitis. Allergy 54:436–445CrossRefPubMed
28.
Zurück zum Zitat Gevaert P, Bachert C, Holtappels G et al (2003) Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis. Allergy 58:371–379CrossRefPubMed Gevaert P, Bachert C, Holtappels G et al (2003) Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis. Allergy 58:371–379CrossRefPubMed
29.
Zurück zum Zitat Simon HU, Yousefi S, Schranz C et al (1997) Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 158:3902–3908PubMed Simon HU, Yousefi S, Schranz C et al (1997) Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 158:3902–3908PubMed
33.
Zurück zum Zitat Joo YH, Chang DY, Kim JH et al (2016) Anti-inflammatory effects of intranasal cyclosporine for allergic rhinitis in a mouse model. Int Forum Allergy Rhinol 6(11):1139–1144. doi:10.1002/alr.21808 CrossRefPubMed Joo YH, Chang DY, Kim JH et al (2016) Anti-inflammatory effects of intranasal cyclosporine for allergic rhinitis in a mouse model. Int Forum Allergy Rhinol 6(11):1139–1144. doi:10.​1002/​alr.​21808 CrossRefPubMed
Metadaten
Titel
Assessment of the effectiveness of cyclosporine nasal spray in an animal model of allergic rhinitis
verfasst von
Erol Senturk
Yavuz Selim Yildirim
Remzi Dogan
Orhan Ozturan
Eray Metin Guler
Mehmet Serif Aydin
Abdurrahim Kocyigit
Mukaddes Esrefoglu
Ilker Kocak
Publikationsdatum
25.10.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Archives of Oto-Rhino-Laryngology / Ausgabe 1/2018
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-017-4786-2

Weitere Artikel der Ausgabe 1/2018

European Archives of Oto-Rhino-Laryngology 1/2018 Zur Ausgabe

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.